Last reviewed · How we verify
NCT06362577: HIFU
Clinical Study of HIFU for Localized Prostate Cancer
trial testing EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG in Localized Prostate Cancer in 60 participants. Currently enrolling.
30 November 2025
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 21 May 2024 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG
Conditions studied
- Localized Prostate Cancer — all drugs for Localized Prostate Cancer →
Sponsor
RenJi Hospital
Who can join
40 and older, male only, with Localized Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the safety and effectiveness data of Sonablate system, a transrectal high-intensity focused ultrasound therapeutic instrument, in the treatment of localized prostate cancer were collected, and the treatment conditions of patients with other methods (such as radical prostatectomy) were compared and analyzed. Observe the differences in treatment effect, survival rate, postoperative PSA, recurrence and complications. To analyze and compare the clinical outcome, postoperative complications and tumor control of HIFU and robot-assisted laparoscopic radical prostatectomy for localized prostate cancer, and to explore the effectiveness and safety of HIFU in the treatment of localized prostate cancer, so as to provide an alternative treatment for localized prostate cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06362577
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Localized Prostate Cancer
Currently open trials in the same condition.
- NCT06966778 — Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial · NA · recruiting
- NCT06825091 — Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE) · Phase 3 · recruiting
- NCT06117059 — The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance · NA · recruiting
- NCT06325774 — Radical Hypofractionated Radiotherapy for Localized Prostate Cancer · NA · recruiting
- NCT06325995 — Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer · NA · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06362577 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 15 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06362577.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing